1) Melanoma
[英][,melə'nəʊmə] [美]['mɛlə'nomə]
肝动脉泵生物化疗
1.
Hepatic Intra-arterial Bio-chemotherapy for the Treatment of Melanoma Patients with Liver Metastasis:A Phase Ⅱ Clinical Study;
肝动脉泵生物化疗治疗进展期黑色素瘤肝转移Ⅱ期临床研究
2) electrochemical therapy
肝动脉插管置泵化疗
1.
Clinical report of 75 cases of advanced hepatic carcinoma treated by electrochemical therapy and intermittent hepatic arterial infusion chemotherapy;
电化学治疗联合肝动脉插管置泵化疗治疗中晚期肝癌75例疗效观察
3) hepatic artery chemoembolization
肝动脉化疗
1.
Therapy using baraclude and hepatic artery chemoembolization(TACE)is helpful to prolong the survival for paitents with hepatocellular carcinoma(HCC)with coexisting active hepatitis B;
博路定联合肝动脉化疗对HBsAg(+)肝癌病人生存期的影响
4) Transcatheter arterial chemoembolization
肝动脉化疗栓塞
1.
Therapeutic effect of transcatheter arterial chemoembolization combined with percutaneous ethanol injection for treatment of moderete and late stage liver cancer;
肝动脉化疗栓塞联合无水乙醇注射治疗中晚期肝癌的近期疗效观察
2.
Development in radiotherapy combined with transcatheter arterial chemoembolization for primary liver cancer.;
放疗联合肝动脉化疗栓塞治疗肝癌的研究进展
3.
Effect of transcatheter arterial chemoembolization on HBV DNA level in primary liver cancer patients
肝动脉化疗栓塞对原发性肝癌患者HBV DNA水平的影响
5) hepatic arterial chemoembolization
肝动脉化疗栓塞
1.
Analysis on electrolytes and liver function indexes of patients after undergoing hepatic arterial chemoembolization;
肝动脉化疗栓塞后电解质和肝功能指标的变化
2.
To observe the short-term effect of Aidi injection and hepatic arterial chemoembolization (TACE) for primary hepatic carcinoma (PHC).
观察艾迪注射液合肝动脉化疗栓塞(TACE)治疗晚期原发性肝癌32例的近期疗效,对照组病人用TACE术治疗,治疗组用TACE术加艾迪注射液治疗,结果:治疗组近期疗效比对照组明显提高,说明艾迪注射液合TACE可有效治疗晚期原发性肝癌,提高患者生活质量,降低毒副作用。
3.
Transcather arterial chemoembolization (TACE), also called hepatic arterial chemoembolization (HACE), is considered a secure, effective and repeatable first selecting conventional therapy for the inoperable hepatama.
经导管动脉内化疗栓塞术(transcather arterial chemoembolization, TACE)又称肝动脉化疗栓塞治疗,是目前公认为对不能手术切除的原发性肝癌的安全、有效、可反复的首选常规治疗方法,它近期疗效显著,可使肿瘤缩小,症状缓解,并有效杀灭肿瘤细胞,在一定时间内控制肿瘤的生长,延长患者生存时间。
补充资料：卵巢癌动脉内化疗
卵巢癌动脉内化疗
此化疗系指将抗癌药物注入卵巢癌的营养动脉，使抗癌药物在组织内浓度增高，提高其抗肿瘤效果，减少全身分布，减轻不良反应。方法是在手术时，将导管插入肿瘤的营养血管，或暴露腹壁下动脉或股动脉逆行插入导管，随后注入化疗药物。更常用的是经皮穿刺插入导管，常用为Seldinger,Cobra和Headhuter等导管，通过股动脉在X线直视下插入导管至所需灌注的动脉，如需反复灌注，可将导管末端连接在埋藏在皮下的药物泵，以后可经皮肤反复穿刺给药。在动脉化疗前，应先进行肿瘤区的血管造影，也肯定导管是否进入主供血管。动脉内灌注时，卵巢癌局部药物浓度较血液中浓度高，而血液中反跳浓度则出现较晚。最常用的药物为阿霉素、顺铂、卡铂、足叶乙甙等。有时可配合全身化疗同时应用，所用的药物可和全身化疗一样。动脉内灌注常可同时进行供血动脉栓塞。这样可控制手术时出血和使周围组织在手术时易于分离。动脉内化疗、灌注动脉选择常分为3种：1.亚选择性：导管插入腹主动脉第3腰椎水平。2.选择性：导管插入髂内动脉。3.超选择性：导管插入卵巢动脉或肿瘤供血动脉。
说明：补充资料仅用于学习参考，请勿用于其它任何用途。
参考词条